Targeted protein degradation – New modalities and design technologies
In the attempt of treating all human diseases, the realization of a cohort of targets being deemed as ‘undruggable’ is a growing market in therapeutics. With more and more researchers focusing on these targets, it has unveiled the opportunity to expand our knowledge of these larger and more complex proteins that fail to fit into conventional drug design strategies.
‘Out-of-the-box’ approaches are driving pharmaceutical developments forward with encouraging results. Join Dr. Bernhard Fasching, of Monte Rosa Therapeutics and Dr, Benedict Cross, of PhoreMost Therapeutics, as they share the promising new modalities in drug discovery, unveiling strategies and technologies aimed at targeting previously ‘undruggable’ diseases.
This webinar offers valuable insights for both seasoned researchers and newcomers, enhancing their understanding of the latest advancements in drug discovery, including topics of molecular glue degraders and editing the proteome.
Key learning objectives
- Discover the latest advancements in drug discovery
- Gain insight into molecular glue degraders (features and origins)
- Learn more about targeted protein degradation (editing the proteome)
Who should attend
Researchers in drug discovery, researchers working with ‘undruggable targets’.
Certificate of attendance
All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.
Speakers
Dr. Bernhard Fasching graduated from the University of Dortmund and the Max Planck Institute fur Kohlenforschung. Following this, he completed a post-doc at Memorial Sloan Kettering working on glycopeptide synthesis. As head of chemistry at Monte Rosa Therapeutics, he leads medicinal chemistry teams with a focus on the creation of biotech platforms centered around novel modes of action such as molecular glue degraders as well as mechanisms of ternary complexes.
Dr. Benedict Cross received his doctorate from the University of Manchester in biochemistry. He joined PhoreMost as the Senior Director of Technology, before moving into his current position as the Chief Technology Officer. He uses programmed mini-protein perturbagens to uncover new drug targets and has applied this in the protein degradation field. His research interests include protein biogenesis, proteostasis, targeted protein degradation (TPD) and functional genomic screening.
Moderator
